XTER:QIA (Netherlands)  
Qiagen NV logo

Qiagen NV

€ 47.56 (+0.3%) Nov 28
On watch
P/E:
24.36
P/B:
3.35
Market Cap:
€ 10.71B ($ 11.07B)
Enterprise V:
€ 11.10B ($ 11.47B)
Volume:
457.53K
Avg Vol (2M):
502.09K
Also Trade In:
Volume:
457.53K
Market Cap €:
10.71B
Market Cap $:
11.07B
PE Ratio:
24.36
Avg Vol (2-Month):
502.09K
Enterprise Value €:
11.10B
Enterprise Value $:
11.47B
PB Ratio:
3.35
GF Score:
Year:
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Description
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (45% of 2021 sales), followed by EMEA (36%) and Asia-Pacific (19%).

Financials (Next Earnings Date:2023-02-08 Est.)

XTER:QIA's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 2,078.303
EPS (TTM) (€) 1.865
Beta 0.04
Volatility % 18.77
14-Day RSI 63.24
14-Day ATR (€) 1.081678
20-Day SMA (€) 45.3935
12-1 Month Momentum % -13.3
52-Week Range (€) 37.95 - 50.76
Shares Outstanding (Mil) 227.7

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Qiagen NV Filings

Document Form Filing Date
No Filing Data

Qiagen NV Analysis

Share your research